A sure sign biotech has come of age: On Monday, at the JP MorganHealthcare Conference, Celgene gave guidance all the wayout to 2020. For many years, the biotech had just given a single year's guidance ...

Biopharmaceutical companyCelgene is up more than 400% over the past five years, smashing the market's return and making a small fortune for long-term investors. Despite the huge run, there are plenty ...

Celgene Corporation (NASDAQ:CELG) has emerged as the leading treatment provider for blood cancer. The company value has almost doubled in the last year due to rising sales of Revlimid and approval of ...

SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) today announced the election of John Weiland to its Board of Directors. Mr. Weiland has over 30 years in the healthcare industry and ...

Celgene Corporation (NASDAQ:CELG) announced on Wednesday a $600 million deal to buy a stake in a growing biotech with several successful products on the market and a strong pipeline. Who is this new ...

SUMMIT, N.J. & SAN DIEGO–(BUSINESS WIRE)–Celgene Corporation (NASDAQ:CELG) and Quanticel Pharmaceuticals, Inc., a privately held biotechnology company focused on cancer drug discovery, today announced ...

Company Reports Record Operating Performance in 2007 Driven by Extraordinary Revenue and Profit Growth - Total Revenue for 2007 Increased More Than 50 Percent Year-Over-Year to Approximately $1.4 ...

Presage Biosciences, a leader in discovering effective cancer drug combinations, today announced that it has entered into a strategic collaboration agreement with Celgene Corporation under which ...

SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) today announced that its stockholders have voted to approve the company’s proposed combination with Bristol-Myers Squibb Company (NYSE ...

SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that Celgene has submitted a Biologics License Application ...

SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Cowen and Company 31 st Annual Health Care Conference on Wednesday, March 9, 2011 at 10:15 ...

Celgene Corporation CELG is expected to significantly benefit from key drug Revlimid's performance in the upcoming quarterly results. The company has surpassed earnings estimates in the trailing four ...